"Anagrelide in treatment of ET and MPS with trombocytemia in Czech Republic"@en . "Hada\u010Dov\u00E1, I." . "\u010Cern\u00E1, O." . "Szotkowski, T." . . "Hlu\u0161\u00ED, A." . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . . "Seghetov\u00E1, J." . "Vr\u00E1nov\u00E1, M." . . "Doubek, M." . "Hochov\u00E1, I." . . "Anagrelid-hydrochlorid je \u00FA\u010Dinn\u00E1 l\u00E1tka pou\u017E\u00EDvan\u00E1 u pacient\u016F s ET a jin\u00FDmi myeloproliferativn\u00EDmi poruchami s trombocytemi\u00ED k selektivn\u00EDmu sn\u00ED\u017Een\u00ED po\u010Dtu trombocyt\u016F. Indikace pro pou\u017Eit\u00ED anagrelidu byly podrobn\u011B pops\u00E1ny v \u010Desk\u00E9 l\u00E9ka\u0159sk\u00E9 literatu\u0159e. Od roku 2005 se data t\u00FDkaj\u00EDc\u00ED se zach\u00E1zen\u00ED s anagrelidu na n\u011Bkter\u00FDch l\u00E9ka\u0159sk\u00FDch klinik\u00E1ch shroma\u017E\u010Fuj\u00ED v evidenci pacien\u016Ft b\u011Bhem l\u00E9\u010Dby z roku 2004, kdy l\u00E9k, kter\u00FD m\u011Bl b\u00FDt pou\u017Eit p\u0159i l\u00E9\u010Db\u011B trombocytemie u myeloproliferativn\u00EDch poruch, z\u00EDskal registraci od St\u00E1tn\u00EDho \u00FAstavu pro kontrolu l\u00E9\u010Div. C\u00EDlem rejst\u0159\u00EDku pacient\u016F je sledovat l\u00E9ka\u0159sk\u00E9 \u00FA\u010Dinky l\u00E9\u010Dby anagrelidem a v\u00FDskyt ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F u pacient\u016F s ET a dal\u0161\u00EDmi myeloproliferativn\u00EDmi poruchami a n\u00E1sledn\u00E9 anal\u00FDza z\u00EDskan\u00FDch \u00FAdaj\u016F. V sou\u010Dasn\u00E9 dob\u011B rejst\u0159\u00EDk pacient\u016F obsahuje \u00FAdaje od 154 pacient\u016F."@cs . "Lho\u0165anov\u00E1, T." . "\u0160irok\u00FD, O." . . "Dul\u00ED\u010Dek, P." . "Kissov\u00E1, J." . "Voglov\u00E1, J." . "52" . "Belada, D." . "Du\u0161ek, L." . "Schwarz, Ji\u0159\u00ED" . . . . "Vozobulov\u00E1, V." . "Anagrelide in treatment of ET and MPS with trombocytemia in Czech Republic"@en . "2"^^ . . "S, V" . . "6"^^ . . "anagrelid (Thromboreductine); treatment; thrombocythemia; Czech Republic"@en . "Anagrelid v l\u00E9\u010Db\u011B esenci\u00E1ln\u00ED trombocytemie a dal\u0161\u00EDch myeloproliferac\u00ED s trombocytemi\u00ED sledovan\u00FDch v registru pacient\u016F v \u010CR"@cs . "Anagrelide hydrochloride is an effective drug used in patients with ET and other myeloproliferative disorders with thrombocythemia to selectively decrease the number of thrombocytes. Indications for use of anagrelide were described in detail in Czech medical literature. Since 2005 data concerning treatment with anagrelide in some medical clinics have been collected in patient register showing course of treatment from 2004, when the medicament obtained marketing authorization from State Institute for Drug Control to be used in the treatment of thrombocythemia in myeloproliferative disorders. Aim of patient register is to monitor medical effect of anagrelide therapy and incidence of adverse effects in patients with ET and other myeloproliferative disorders and subsequent analysis of collected data. At the moment patient register contains data from 154 patients."@en . . "Buben\u00EDk, B." . "0042-773X" . "5" . "Pytl\u00EDk, R." . . "RIV/00023736:_____/06:00006651!RIV09-MZ0-00023736" . "Brychtov\u00E1, Y." . "Anagrelid v l\u00E9\u010Db\u011B esenci\u00E1ln\u00ED trombocytemie a dal\u0161\u00EDch myeloproliferac\u00ED s trombocytemi\u00ED sledovan\u00FDch v registru pacient\u016F v \u010CR"@cs . "464853" . "Anagrelid v l\u00E9\u010Db\u011B esenci\u00E1ln\u00ED trombocytemie a dal\u0161\u00EDch myeloproliferac\u00ED s trombocytemi\u00ED sledovan\u00FDch v registru pacient\u016F v \u010CR" . "RIV/00023736:_____/06:00006651" . . "24"^^ . "CZ - \u010Cesk\u00E1 republika" . "Penka, M." . "Volkov\u00E1, Zuzana" . . "Mi\u010Dan\u00EDkov\u00E1, M." . "Sch\u00FCtzov\u00E1, M." . "[A2C85F97D792]" . "Anagrelid v l\u00E9\u010Db\u011B esenci\u00E1ln\u00ED trombocytemie a dal\u0161\u00EDch myeloproliferac\u00ED s trombocytemi\u00ED sledovan\u00FDch v registru pacient\u016F v \u010CR" . . "Anagrelid-hydrochlorid je \u00FA\u010Dinn\u00E1 l\u00E1tka pou\u017E\u00EDvan\u00E1 u pacient\u016F s ET a jin\u00FDmi myeloproliferativn\u00EDmi poruchami s trombocytemi\u00ED k selektivn\u00EDmu sn\u00ED\u017Een\u00ED po\u010Dtu trombocyt\u016F. Indikace pro pou\u017Eit\u00ED anagrelidu byly podrobn\u011B pops\u00E1ny v \u010Desk\u00E9 l\u00E9ka\u0159sk\u00E9 literatu\u0159e. Od roku 2005 se data t\u00FDkaj\u00EDc\u00ED se zach\u00E1zen\u00ED s anagrelidu na n\u011Bkter\u00FDch l\u00E9ka\u0159sk\u00FDch klinik\u00E1ch shroma\u017E\u010Fuj\u00ED v evidenci pacien\u016Ft b\u011Bhem l\u00E9\u010Dby z roku 2004, kdy l\u00E9k, kter\u00FD m\u011Bl b\u00FDt pou\u017Eit p\u0159i l\u00E9\u010Db\u011B trombocytemie u myeloproliferativn\u00EDch poruch, z\u00EDskal registraci od St\u00E1tn\u00EDho \u00FAstavu pro kontrolu l\u00E9\u010Div. C\u00EDlem rejst\u0159\u00EDku pacient\u016F je sledovat l\u00E9ka\u0159sk\u00E9 \u00FA\u010Dinky l\u00E9\u010Dby anagrelidem a v\u00FDskyt ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F u pacient\u016F s ET a dal\u0161\u00EDmi myeloproliferativn\u00EDmi poruchami a n\u00E1sledn\u00E9 anal\u00FDza z\u00EDskan\u00FDch \u00FAdaj\u016F. V sou\u010Dasn\u00E9 dob\u011B rejst\u0159\u00EDk pacient\u016F obsahuje \u00FAdaje od 154 pacient\u016F." . .